Related Experiment Video

Updated: Apr 24, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

12.5K

Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer

Hong Jin1, Yundan Liang, Xunli Wang

  • 1Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.

Medical Oncology (Northwood, London, England)
|September 10, 2014
PubMed

Insights

The KRAS rs712 genetic variant may influence papillary thyroid cancer (PTC) progression. Individuals with the TT genotype showed reduced likelihood of advanced PTC stages, suggesting its potential as a biomarker.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • KRAS mutations are common in various cancers, including papillary thyroid cancer (PTC).
  • A specific KRAS genetic variant (rs712) in the 3' UTR may affect gene regulation by interacting with microRNAs.
  • The clinical significance of the KRAS rs712 polymorphism in PTC development and progression requires investigation.

Purpose of the Study:

  • To investigate the association between the KRAS rs712 polymorphism and the risk of developing papillary thyroid cancer.
  • To determine if the KRAS rs712 polymorphism is a risk factor for PTC.
  • To explore the potential role of KRAS rs712 in PTC staging.

Main Methods:

  • An association study was conducted with 252 PTC patients and 290 healthy controls.
  • Genotyping of the KRAS rs712 polymorphism was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • Statistical analysis included overall and stratification analyses under different genetic models.

Main Results:

  • No significant difference in KRAS rs712 distribution was found between PTC cases and controls overall.
  • Stratification analysis revealed that patients with the KRAS rs712 TT genotype had a reduced likelihood of developing stages T3 and T4 PTC (OR 0.26, 95% CI 0.08-0.82) under a recessive model.
  • These findings suggest a potential link between the KRAS rs712 TT genotype and less advanced tumor stages.

Conclusions:

  • The KRAS rs712 polymorphism may not be a significant risk factor for overall PTC development.
  • The KRAS rs712 TT genotype appears to be associated with a lower risk of advanced PTC (stages T3-T4).
  • The KRAS rs712 polymorphism could serve as a potential genetic biomarker for predicting PTC tumor extension, warranting further validation in diverse populations.

More Related Videos

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K